Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
Novavax RSV vaccine reported positive PhII data
Aug. 17, 2015
Last week, Novavax announced that its respiratory syncytial virus(RSV) candidate vaccine prevented 64% of severe RSV cases, 44% of all symptomatic RSV cases and 46% of RSV disease with lower respiratory tract symptoms in older adults. Currently there is no vaccine for respiratory syncytial virus, which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65.
UK began nation-wide Men B vaccination
Sep. 6, 2015
Last month, UK started a nation-wide Men B vaccination program to protect young children against the potentially fatal disease meningitis B. GSK Men B vaccines are offered to babies at the ages of two months, four months and 12-13 months.
Merck and Samsung notched their first biosimilar victory in South Korea
Sep. 8, 2015
Merck and Samsung Bioepis recorded their first approval in South Korea for their copy of Amgen's blockbuster Enbrel. The biosimilar will be marketed as Brenzys, to treat rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and psoriasis in adults.
Serum Institute seeks fast track for dengue treatment
Sep. 25, 2015
The Serum Institute of India is seeking fast-track approval to launch a dengue treatment in India, expecting to get approval in a year to a year and a half. If successful, the company could be the first to launch a drug for dengue globally. Sanofi also plans to launch its vaccine in 20 countries by the end of this year.
Advaxis reported encouraging PhII cervical cancer vaccine data
Sep. 28, 2015
Advaxis reported encouraging data In the first stage of a Phase II study of its cervical cancer vaccine candidiate, axalimogene filolisbac (ADXS-HPV), with 38.5% of patients who previously failed at least one line of therapy alive after 12 months and given an estimated four to 7 months to live. However in 17 previous studies of investigational agents conducted by the Gynecologic Oncology Group, the 12-month survival rate has never been above 30%.
Pfizer completes $130 million purchase of two GSK Meningitis vaccines
Oct. 9, 2015
Pfizer has recently completed the $130 million acquisition of two GSK's Men ACWY vaccines Nimenrix and Mencevax, ACWY-TT conjugated vaccine and ACWY polysaccharide vaccine respectively. In 2014, Pfizer got US FDA approval for its Men B vaccines for individuals aged 10 to 25 years.
Inovio's MERS vaccine could hit PhI this year
Oct. 21, 2015
Currently there is no vaccine for MERS, but Inovio has filed an Investigational New Drug Application for its candidate vaccine and might bring the jab to Phase I before the end of this year. The vaccine showed 100% protection from a live virus challenge in mice, camels and monkeys.
Sanofi, Gates Foundation and IDRI team up to improve vaccine's accessibility and affordability
Oct.27, 2015
Sanofi Pasteur, the Bill & Melinda Gates Foundation and the Infectious Disease Research Institute (IDRI) recently joined together to create the Global Health Vaccine Center of Innovation (GHVCI), aiming at making a new, cheaper model for vaccines development, with Sanofi Pasteur bringing its vaccine development and commercialization experiences, IDRI contributing its vaccine adjuvant and formulation expertise and the Gates Foundation's financial support.
Sanofi expects to get its dengue vaccine approved this Q4
Nov. 4, 2015
Sanofi expects to get the license for its dengue vaccine by the end of this year and launch the vaccine next year. So far, Sanofi has spent 20 years and $1.5 billion to develop the vaccine
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next